Stayble Therapeutics AB (STU:4K4) Dividends per Share : €0.00 (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Dividends per Share?

Stayble Therapeutics AB's dividends per share for the three months ended in Sep. 2023 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2023 was 0.00. As of today, Stayble Therapeutics AB's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

Stayble Therapeutics AB Dividends per Share Historical Data

The historical data trend for Stayble Therapeutics AB's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Dividends per Share Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividends per Share

Get a 7-Day Free Trial

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Stayble Therapeutics AB's Dividends per Share

For the Biotechnology subindustry, Stayble Therapeutics AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Dividend Yield % falls into.

Stayble Therapeutics AB Dividends per Share Calculation

Dividends paid to per common share.

Stayble Therapeutics AB (STU:4K4) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Stayble Therapeutics AB's Dividend Payout Ratio for the quarter that ended in Sep. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2023 )	/	EPS without NRI (Q: Sep. 2023 )
	=	0	/	-0.019
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Stayble Therapeutics AB Dividends per Share Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (STU:4K4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

STABL:Sweden 4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines